Heres the honest truth: microdosing GLP-1s might be the future of preventive longevity careor it might be a shiny distraction from the foundations we know work
At the same time, payer policies often require discontinuation of GLP-1 therapy when a patients BMI drops below a set threshold, inadvertently triggering a frustrating cycle of weight loss and regainthe so-called yo-yo effect. This not only impacts ongoing adherence and persistence but also undermines the long-term cost-effectiveness of these therapies for healthcare systems
Store Saxenda as directed by healthcare professionals
Hormonal optimization is often the missing piece
This patient experienced long-lasting improvement of psoriasis that was previously refractory to biologics, suggesting that severe, resistant lesions may benefit from GLP-1 agonist therapy
About 20 years ago, she underwent gastric bypass surgery, which helped her go from 300 to 190 pounds